
Chinese clinical-stage biopharmaceutical company in Zhuhai, Guangdong, developing innovative and improved new drugs to give patients safer and more effective anticancer medicines. Holds twelve granted invention patents and more than seventy patent applications, and has built a platform technology that raises the solubility of poorly soluble injectable drugs, supporting a pipeline of more than ten candidates in oncology and pain. Its lead improved docetaxel programme BH009, marketed in the United States as BEIZRAY, has clearance for clinical trials from both the US FDA and China's CDE and was licensed out with an upfront payment of close to 200 million yuan.
留下您的评分